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ABSTRACT
Europe has contributed to the majority of high-impact papers on genes and risk 
alleles in breast cancer and ovarian cancer susceptibility. Consortia like the Breast 
Cancer Linkage Consortium, Breast Cancer Association Consortium, and the 
Consortium of Investigators on Modifying genes in BRCA1/2, started from the 
nineties of the last century on.  Many highly motivated participants throughout 
Europe, the US, Australia, and elsewhere contributed to the formation of huge 
data sets. Instrumental of the success of the consortia was also the leadership 
and knowledge of Dough Easton, UK, on the statistics of cancer genetics. The 
consortia papers have produced the data from which national guidelines in 
HBOC were formulated in West-Europe, the US, and worldwide. Genetic testing 
for HBOC is accepted and funded in most Western-European countries. Two 
decades after the identification of BRCA1 and BRCA2, the attitudes towards 
genetic testing for HBOC are changing and becoming more ‘common’ practice. 
This offers opportunities to organize cancer genetics care more efficiently and at 
lower costs, while informed decision making and consent of the patients remain 
in place. 
Keywords: BRCA1, BRCA2, HBOC, Europe, Founder mutations, linkage
